Tumor Prognosis
Tumor Prognosis - Related Videos
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 8 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
03:17
Preparing Organoids from Tumors: A 3D In Vitro Tumor Model
0 Views •
2023
Organoids derived from tumors are a type of 3D cell culture model that can maintain the pathological features and organ-specific cell lineage of tumors. In the example protocol, we will see scientists generate organoids from a prostate tumor from a genetically engineered mouse model.
01:29
Anti-Tumor Effects of Engineered Pediococcus pentosaceus in a Mouse Tumor Model
0 Views •
2026
Begin with immunodeficient mice bearing subcutaneous xenograft tumors derived from human colorectal cancer cells.Orally administer Pediococcus pentosaceus, a lactic acid bacterium safe for consumption and engineered to secrete an anticancer protein, to the treated mouse.Administer saline to the control mouse.Being acid-tolerant, the bacteria survive the acidic environment of the stomach and reach the intestine.There, they colonize the intestinal lumen and secrete the anticancer protein.The...
FAQs
Using several tumor features together is important because no single measurement captures every dimension of likely disease behavior. Stage, tumor size, grade, and histologic features contribute complementary information, while molecular biomarkers can add biological detail. Combining these inputs supports more informative risk estimates than relying on one characteristic alone and helps distinguish patients with different expected outcomes.
Molecular biomarkers can reveal biological features associated with either aggressive disease or treatment-responsive disease. Their value comes from adding information that may not be apparent from tumor size, stage, or routine histologic assessment. In cancer research, these markers help investigators connect measurable tumor biology with outcome patterns and improve risk stratification.
An initial estimate is not necessarily fixed because subsequent evidence can change the expected course. Treatment response provides information about how the disease behaves under therapy, while follow-up data add outcomes from the patient’s continuing care. Updating estimates over time can support better surveillance planning and more informed discussions.
Clinicians estimate tumor prognosis by combining disease characteristics with patient and outcome information. Relevant inputs include stage, size, grade, histologic features, molecular biomarkers, treatment response, and overall health. Statistical models and results from comparable patient groups help translate these observations into an evidence-based estimate rather than relying on an isolated finding.
Prognostic information supports several care decisions without serving as a substitute for clinical judgment. It can guide patient counseling, clarify surveillance planning, and contribute to risk stratification. These uses help organize follow-up and communication around the patient’s estimated risk while allowing clinicians to incorporate new evidence as care progresses.
Tumor prognosis is important in cancer research because it provides an outcome framework for comparing therapies and studying disease biology. Prognostic measures can contribute to study design, help evaluate treatment effects, and identify biological features associated with aggressive or treatment-responsive disease. This connects patient outcomes with research questions about risk and therapeutic benefit.